<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>LLC - Le Fonti New Pharma Italy</title>
	<atom:link href="https://www.newpharmaitaly.it/tag/llc/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/tag/llc/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Tue, 04 Dec 2018 15:57:21 +0000</lastBuildDate>
	<language>it-IT</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.newpharmaitaly.it/wp-content/uploads/2022/12/cropped-favicon-new-pharma-italy-32x32.jpg</url>
	<title>LLC - Le Fonti New Pharma Italy</title>
	<link>https://www.newpharmaitaly.it/tag/llc/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Rivaroxaban protegge contro l’ictus più del warfarin</title>
		<link>https://www.newpharmaitaly.it/rivaroxaban-protegge-contro-ictus-piu-del-warfarin/</link>
		
		<dc:creator><![CDATA[Elvis Kondi]]></dc:creator>
		<pubDate>Tue, 04 Dec 2018 15:57:21 +0000</pubDate>
				<category><![CDATA[Innovazione]]></category>
		<category><![CDATA[American Heart Association]]></category>
		<category><![CDATA[Bayer AG]]></category>
		<category><![CDATA[Fibrillazione Atriale non-valvolare]]></category>
		<category><![CDATA[ictus]]></category>
		<category><![CDATA[Janssen Research & Development]]></category>
		<category><![CDATA[LLC]]></category>
		<category><![CDATA[Mark Alberts]]></category>
		<category><![CDATA[rivaroxaban]]></category>
		<category><![CDATA[warfarin]]></category>
		<guid isPermaLink="false">https://www.newpharmaitaly.it/?p=3311</guid>

					<description><![CDATA[<p>Negli Stati Uniti uno studio retrospettivo su oltre 20.000 pazienti con Fibrillazione Atriale non-valvolare conferma i benefici di rivaroxaban Bayer AG e il suo partner di sviluppo Janssen Research &#38; Development, LLC hanno presentato, in occasione del Congresso dell’American Heart Association (AHA) tenutosi il 10-12 novembre 2018, nuovi risultati di real life sulla riduzione significativa [&#8230;]</p>
<p>L'articolo <a href="https://www.newpharmaitaly.it/rivaroxaban-protegge-contro-ictus-piu-del-warfarin/">Rivaroxaban protegge contro l’ictus più del warfarin</a> proviene da <a href="https://www.newpharmaitaly.it">Le Fonti New Pharma Italy</a>.</p>
]]></description>
		
		
		
			</item>
	</channel>
</rss>
